Interpreting the prevalence of regulatory SNPs in cancers and protein-coding SNPs among non-cancer diseases using GWAS association studies by Khalid, Zoya et al.
  
Interpreting the Prevalence of Regulatory SNPs in Cancers and 
Protein-Coding SNPs among Non-Cancer Diseases Using GWAS 
Association Studies 
Zoya Khalid
1§
, Osman Ugur Sezerman
1
 
Abstract— Biological mechanisms underlying 
diseases are quite challenging to understand, as there 
exists a complex relationship between human genetics 
and disease traits. Genome-wide association studies are 
potent methods in identifying single nucleotide 
polymorphisms (SNPs) which are linked with a large 
number of phenotypes. Even though GWAS list down 
the statistically significant SNPs which are found to be 
associated with phenotype of interest, still there is a 
need to look for the direct evidence regarding biological 
processes to better understand the disease development 
mechanism since it may differ in different complex 
diseases depending on the nature of the disease. From 
previous few years, there are above 11 million SNPs that 
have been labelled in databases specifically in dbSNP. 
Among them, the SNPs can be categorized as coding or 
non-coding SNPs depending on their location in the 
genome. Lethal changes in the coding parts of the genes 
might play role in development mechanism of complex 
diseases by directly affecting the functionality of the 
protein. Similarly those SNPs which are present at the 
regulatory regions splice regions, micro RNA binding 
sites and epigenetic sites might affect the level of gene 
expression and ultimately contributes in complex 
disease formation. We designed our study to understand 
the biological mechanism underlying complex diseases 
by performing statistical analysis on GWAS dataset. 
Seventeen different cancer types with the non-cancer 
diseases (autoimmune, Neurodegenerative and 
metabolic diseases) has been selected in order to 
understand the major factors involved in disease 
progression and the impact of SNPs in disease 
development. The statistical analysis includes the chi 
squared hypothesis testing with the null hypotheses H0: 
SNPs in coding and non-coding areas are not 
significantly different and with the alternate hypothesis 
as H1: They are significantly different.The results 
revealed that Complex diseases like Cancer are mostly 
caused by mutations occurring at non coding regulatory 
sites thus causing changes at expression levels of the 
genes involved, such as over expression of oncogenes 
and under expression of tumor suppressor genes as 
expected, whereas in other non-cancer diseases, 
mutations occurring at coding regions of the genes play 
more determinative role. These mutations change the 
functionality of the protein product thus having a direct 
impact on the autoimmune response. This study in 
future can be taken as a reference study for analysing 
coding and non-coding parts of the genome regarding 
divulging biological mechanisms involving complex 
diseases. 
I. INTRODUCTION 
The first drift of large scale genome wide 
association studies (GWAS) has contributed in 
understanding the mechanism underlying complex 
diseases. For some diseases including Breast cancer, 
Prostate, Asthma and type II diabetes there has been 
speedy growth of loci involved in predisposition. 
From the studies it has been found that GWAS 
studies are suitable for the identification of SNP 
variants with effects on phenotype. 
[1]
 The major 
portion of medical research has inclined towards the 
protein-coding mutations owing to the fact that the 
mechanisms underlying the regulatory SNPs are quite 
complicated and still not fully understood. SNPs 
whether in the coding or non-coding areas may be 
detrimental and may contribute in the development of 
complex diseases. Genome Wide Association studies 
which includes hundreds and thousands of SNPs 
which are tested concurrently in large number of 
cases and control samples in order to associate them 
with the complex disease have developed the hunt for 
genetic basis of these diseases. The success of GWAS 
can be seen from the fact that it identified novel SNPs 
and have been hypothesized as valuable tools for 
finding complex disease genes with the help of 
association studies and, afterwards to be used as 
markers for further genetic analysis. 
[2, 3]
 
Understanding a disease etiology is the challenging 
task for biologists as it is the first step for disease 
diagnosis and treatment. Among the complex diseases 
Asthma is one of the types.  Asthma is an 
inflammatory disease of the airways which is 
characterized by intrusion and activation of 
inflammatory cells followed by structural changes. 
These changes are supposed to associate with the 
severity of asthma and moderately with the 
development of progressive lung function weakening. 
The principal mechanism including airway 
angiogenesis in asthma and its detailed clinical 
significance has not yet been fully revealed 
[4]
. 
Asthma is a common, complex disease that is 
affecting more than 300 million people worldwide. 
[5]
 
Similarly rheumatoid arthritis is also a heterogeneous 
autoimmune disease followed by caustic 
inflammation particularly in joints. The pervasiveness 
in the common population is about 0.5% to 1%, and 
among them women are at more risk for developing 
  
the disease.
[6,7]
 Among the cancer types, Prostate 
cancer is the second most common cancer among 
men population. The prostate cancer shares some 
common features with other cancer types like breast 
cancer and the colon cancer. GWAS studies have 
been contributing successfully in identifying common 
variants (SNPs) which are significantly associated 
with the Prostate cancer. 
[8]
 Similarly for the other 
cancer types GWAS appeared to be as a potent tool 
for identifying diseased loci in cancers 
[9]
. 
In this study we selected seventeen different types 
of diseases including both cancer and non-cancer 
phenotypes namely Asthma, Arthritis, Parkinson 
Disease, Crohn’s Disease, Hypertension, Obesity, 
Schizophrenia, Alzheimer, Multiple Sclerosis and for 
cancer types Breast cancer, Prostate cancer, 
Pancreatic, Colorectal, Liver, Esophageal and 
Bladder. We compared the ratio of SNPs distribution 
among all the disease types selected depending on 
their location in the genome by applying chi-squared 
test statistics. 
II. METHODOLOGY 
The methodology has been designed in order to 
find the significant SNPs and to analyse the ratio of 
these top selected significant SNPs in coding and 
non-coding regions of genome among different 
diseases and to further distinguish the driver 
mutations from the neutral ones in the coding regions 
of cancer. The SNP’s were collected from GWAS. 
GWAS usually emphasizes on associations regarding 
single-nucleotide polymorphisms (SNPs) and 
complex diseases. We collected GWAS data for 
different cancer and non-cancer diseases. The 
significant SNP’s were downloaded from 
https://www.gwascentral.org/ 
The significant SNPs are functionalized into 
coding and non-coding genomic regions by using 
SNPnexus Server. It is a functional annotation tool to 
evaluate the likely significance of candidate variants 
which is then linked to the gene/protein isoforms that 
might be phenotypically important. It can be accessed 
through http://www.snp-nexus.org/ 
For statistical inference, Chi-squared Test analysis 
was performed to examine that whether the mutations 
observed in coding regions are significantly different 
form the non-coding ones. 
The following parameters are followed. 
 Alpha value : 0.05 that means 95 % 
confidence interval. 
 If the test statistics value is higher and the P-
value is less than alpha (p< 0.05) the hypothesis is 
rejected that means two variables are statistically 
different. 
 If the test statistics value is lower and the P-
value is higher than alpha (p< 0.05) the hypothesis is 
accepted that means two variables are not statistically 
significant. 
And we took hypothesis as follows 
H0: SNPs in coding and non-coding areas are not 
significantly different. (Null Hypothesis) 
H1: They are significantly different. (Alternate 
hypothesis) 
III. RESULTS 
Starting with the most significant SNPs obtained, 
polymorphisms belonging to selected cancer and non-
cancer types have been analyzed. It has been 
observed that SNPs are occurring at different rates 
depending on their location in the genome i-e coding 
and non-coding areas. Table 1 and 2 summarized the 
distribution of SNPs in coding and non-coding areas 
per disease type and Figure 1 further depicts the 
distribution of non-coding parts intro introns and 
downstream regions. The first part of our study is to 
analyze the ratio of SNPs among cancer and non-
cancer types depending on their genome location. For 
this the chi squared test analysis was performed. The 
two hypotheses selected are mentioned in the 
methods part. From the results it has been observed 
that for cancer diseases the value of test statistic 
obtained was 185.0561 with the p-value 0.000045, 
while for non-cancer ones it was 30.69 with p-value 
3.6315e-08. On the basis of these values obtained it 
has been clear that our null hypothesis has been 
rejected and the alternative hypothesis has been 
accepted. The alternative hypothesis states that the 
SNPs are occurring at significantly different rates in 
the coding and non-coding regions. The results are 
mentioned in Table 3. Furthermore the ratio of coding 
and non-coding SNPs among cancer and non-cancer 
diseases can also be graphically viewed in Figure 2. 
From the figure it has been visualized that in cancer 
like diseases the SNPs are more prevalent in non-
coding parts in comparison to the coding ones, while 
the scenario is quite opposite in non-cancer diseases 
where the coding SNPs are in higher proportion than 
the non-coding ones. 
IV. DISCUSSION 
From previous few years, there are above 11 
million SNPs that have been labelled in databases 
specifically in dbSNP. Among them, the SNPs can be 
categorized into coding and non-coding SNP 
depending on their location in the genome. Lethal 
changes in the coding parts of the genes might play 
role in development mechanism of complex diseases 
by directly affecting the functionality of the protein. 
Similarly those SNPs which are present at the 
regulatory regions splice regions, micro RNA binding 
sites and epigenetic sites might affect the level of 
gene expression and ultimately contributes in 
complex disease formation. Biological mechanisms 
underlying diseases are quite challenging to 
  
understand, as there exists a complex relationship 
between human genetics and disease traits. A 
Mendalian disease can occur as a result of a single 
mutation on a gene that explains all the disease cases, 
however, complex diseases do not associate strongly 
with a single gene mutation, and rather they are 
caused by variant forms of several genes which can 
be the direct result of several single nucleotide 
polymorphisms targeting these genes. Among various 
diseases, cancer is one of the multifactorial diseases 
because of the fact that they are likely associated with 
the effects of multiple genes in permutation with 
additional factors including lifestyle and 
environmental factors. To understand the biology 
behind complex disorders is very challenging, since 
the root cause for most of these disorders have not 
been identified so far. Genome Wide Association 
studies includes hundreds and thousands of SNPs 
which are tested concurrently in large number of 
cases and control samples in order to associate them 
with the complex disease have developed the hunt for 
genetic basis of these diseases. The success of GWAS 
can be seen from the fact that it identified novel 
common genetic risk factors involved with the 
significance of earlier recognized generic variants. 
Hence it is known that concentrating on few SNP and 
genes showing strong association with the disease is 
not sufficient to understand the underlying disease 
mechanism, because there exists a chance that those 
biologically important genetic variants that have a 
small disease risk are might get overlooked. 
Bearing in mind all these factors we designed our 
study to understand the biological mechanism 
underlying complex diseases with GWAS studies.  
We analysed seventeen different types of cancer and 
non-cancer disease (autoimmune, neurodegenerative 
and metabolic). The top selected most significant 
SNPs which are ranked according to their p-values 
are filtered out. The threshold was set to p-value 
<0.05.  We compared the frequency distribution for 
SNPs present in the coding and non-coding regions 
for all the disease types tested in this study. The 
analysis revealed that for cancer diseases more crucial 
part of research is the non-coding or the junk DNA. 
Mutation lying in this region is the regulatory 
mutation, which does not translate into protein but 
still has multiple impacts on disease. The regulatory 
mutations alter the ability of a transcription factor to 
bind to DNA which further affects the gene 
expression level and ultimately leading to disease. 
These regulatory mutations are likely the drug targets, 
so it’s certainly important to look for these mutations 
in order to fully understand the biological process 
behind this and furthermore to target correct drugs for 
treatment and therapies.
[10, 11]
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       Figure 1   Distribution of non-coding SNPs across the genome.  
 
Figure 2 SNP frequencies in coding and non-coding regions of the 
Cancer and Non-Cancer Diseases   
.  
TABLE I DISTRIBUTION OF CODING AND NON-CODING 
SNPS IN CANCER 
  
Cancer Name Coding SNPs 
(Percentage) 
Non-coding 
SNPs 
(Percentage) 
Breast Cancer 10% 90% 
Prostate Cancer 20% 80% 
Liver Cancer 8% 92% 
Pancreatic Cancer 15% 85% 
Colorectal Cancer 18% 82% 
Leukemia 12% 88% 
Bladder Cancer 13% 87% 
Esophageal 
Cancer 
16% 84% 
Total no of SNPs 1818 29025 
TABLE II DISTRIBUTION OF CODING AND NON-CODING 
SNPS IN NON-CANCER DISEASES 
Non-Cancer 
Disease 
Coding SNPs 
(Percentage) 
Non-coding SNPs 
(Percentage) 
Asthma 90% 10% 
Arthritis 85% 10% 
Crohn’s Disease 70% 30% 
Multiple Sclerosis 80% 20% 
Parkinson Disease 78% 22% 
Obesity 75% 25% 
Hypertension 90% 10% 
Alzheimer 85% 10% 
Schizophrenia 80% 20% 
Total Number of 
SNPs 
2025 750 
TABLE III   SUMMARY OF CHI SQUARE TEST STATISTIC 
Mutations Chi-squared Test Statistic P-value 
Cancer 185.0561 0.000045 
Non-Cancer   30.369 3.6315e-08 
V. CONCLUSION 
The analysis revealed that Complex diseases like 
Cancer are mostly caused by mutations occurring at 
non coding regulatory sites thus causing changes at 
expression levels of the genes involved, such as over 
expression of oncogenes and under expression of 
tumor suppressor genes as expected. Whereas in 
other non-cancer diseases (autoimmune diseases, 
metabolic and Neurodegenerative diseases), 
mutations occurring at coding regions of the genes 
play a more determinative role. These mutations 
change the functionality of the protein product thus 
having a direct impact on the autoimmune response. 
This study in future can be taken as a reference study 
for analysing coding and non-coding parts of the 
genome regarding divulging biological mechanisms 
involving complex diseases 
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